Cytek Biosciences vs Maravai Lifesciences Holdings
Cytek Biosciences and Maravai Lifesciences Holdings are similar in size: $201m and $186m of revenue in their latest fiscal years. Cytek Biosciences grew faster (0.5% against -28.3%). Cytek Biosciences kept more of each dollar of sales as profit: a net margin of -33.0% against -70.4%. Cytek Biosciences carries less debt relative to equity (0.2% against 138.5%).
| Latest fiscal year | Cytek BiosciencesCTKB, 2025 | Maravai Lifesciences HoldingsMRVI, 2025 |
|---|---|---|
| Revenue | $201m | $186m |
| Revenue growth | 0.5% | -28.3% |
| Net income | −$66.5m | −$131m |
| Operating margin | -20.0% | -115.9% |
| Net margin | -33.0% | -70.4% |
| Return on equity | -18.0% | -48.6% |
| Free cash flow | −$8.8m | −$70.7m |
| Cash | $90.9m | $217m |
| Total debt | $525,000 | $294m |
| Debt to equity | 0.2% | 138.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $15.1m | — |
| Employees | 702 | 435 |
| Market value | $774m | $1.11bn |
| Price vs our value range | — | — |
| Moat score | 36 (Weak) | 23 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 5 buys, 2 sales |